AV Arabidol
K |
K |
||
| Zeile 1: | Zeile 1: | ||
{{up|PHA antivirals by mechanism}} | {{up|PHA antivirals by mechanism}} | ||
| + | ---- | ||
| + | drug: arabidol, synonym umifenovir | ||
| + | ---- | ||
{{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}} | {{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}} | ||
| Zeile 10: | Zeile 13: | ||
{{tp|p=32474860|t=2020. Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study.|pdf=|usr=008}} | {{tp|p=32474860|t=2020. Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study.|pdf=|usr=008}} | ||
{{tp|p=32283143|t=2020. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.|pdf=|usr=008}} | {{tp|p=32283143|t=2020. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32617989|t=2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=012}} | ||
| + | {{tp|p=32866534|t=2020. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.|pdf=|usr=018}} | ||
| + | {{tp|p=32941741|t=2020. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.|pdf=|usr=019}} | ||
| + | {{tp|p=C7726270|t=2020. (umifenovir) Multiple drugs: Undetectable IgG and IgM levels and off-label use: case report.|pdf=|usr=023}} | ||
Version vom 11. April 2021, 09:33 Uhr
| PHA antivirals by mechanism |
drug: arabidol, synonym umifenovir
32373347 2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
32360231 ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?
32171872 ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
32388937 2020. [Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19 : an observational cohort study].
32510169 2020. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.
32496210 2020. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.
32574310 2020. Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals.
32474860 2020. Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study.
32283143 2020. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
32617989 2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
32866534 2020. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
32941741 2020. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.
C7726270 2020. (umifenovir) Multiple drugs: Undetectable IgG and IgM levels and off-label use: case report.
